New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk

New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk.

This is a case of labeling catching up with the evidence.

Bisphosphonates persist in the bones for years, so 3 to 5 years of therapy is enough for many patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote